Genzyme

Insider Insights: Larry Blankstein, Genzyme

Monday, March 2, 2015

CWWeekly’s semi-monthly company profile feature, Insider Insights, interviews executives of companies and organizations in the clinical trials space. Staff Writer Ronald Rosenberg sat down with Larry Blankstein, senior director of clinical development at Genzyme.

[Read More]

Pharming appoints Dr. Perry Calias chief scientific officer

Thursday, February 19, 2015

Pharming Group has appointed Dr. Perry Calias chief scientific officer. Calias will have overall responsibility for the company’s new enzyme replacement therapy (ERT) programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.

[Read More]

Voyager Therapeutics, Genzyme collaborate on CNS disorders

Thursday, February 12, 2015

Voyager Therapeutics, a gene therapy company headquartered in Cambridge, Mass. developing treatments for diseases of the central nervous system (CNS), and Genzyme, a Sanofi company and gene therapy pioneer, have announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. The collaboration will leverage Genzyme’s long-standing commitment and experience in adeno-associated virus (AAV) gene therapy and Voyager’s AAV product engine to develop breakthrough therapies for patients suffering from severe CNS disorders.

[Read More]

First MS patients in the U.S. receive Genzyme’s Lemtrada following FDA approval

Thursday, December 4, 2014

Genzyme, a Sanofi company, has announced that the first U.S. patients have initiated treatment with Lemtrada (alemtuzumab) in the commercial setting following its Nov. 14 FDA approval for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

[Read More]

Fidelity Biosciences and Atlas Venture launch Unum Therapeutics

Wednesday, October 22, 2014

Fidelity Biosciences and Atlas Venture, with participation from SanofiGenzyme BioVentures, have launched Unum Therapeutics, a company developing cellular immunotherapy to treat cancer. Fidelity Biosciences invests venture capital in biopharmaceutical, medical technology, healthcare information technology and healthcare service companies, while Atlas Venture is an early-stage investor. All three are based in Cambridge, Mass.

[Read More]

FDA expands approval of Lumizyme to treat Pompe disease

Monday, August 4, 2014

The FDA has approved Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are less than eight years of age. In addition, the risk evaluation and mitigation strategy (REMS) known as the Lumizyme ACE (Alglucosidase Alfa Control and Education) Program is being eliminated.

[Read More]